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Antitumor efficacy of systemically administered oncolytic adenoviruses (OAdv) is limited due to diverse factors such as liver
sequestration, neutralizing interactions in blood, elimination by the immune system, and physical barriers in tumors. It is
therefore of clinical relevance to improve OAdv bioavailability and tumor delivery. Among the variety of tumor-targeting
strategies, the use of stem cells and specifically bone marrow-derived mesenchymal stem cells (BM-MSCs) is of particular
interest due to their tumor tropism and immunomodulatory properties. Nonetheless, the invasive methods to obtain these cells,
the low number of MSCs present in the bone marrow, and their restricted in vitro expansion represent major obstacles for their
use in cancer treatments, pointing out the necessity to identify an alternative source of MSCs. Here, we have evaluated the use
of menstrual blood-derived mesenchymal stem cells (MenSCs) as cell carriers for regional delivery of an OAdv in the tumor.
Our results indicate that MenSCs can be isolated without invasive methods, they have an increased proliferation rate
compared to BM-MSCs, and they can be efficiently infected with different serotype 5-based capsid-modified adenoviruses,
leading to viral replication and release. In addition, our in vivo studies confirmed the tumor-homing properties of MenSCs
after regional administration.
1. Introduction
Oncolytic adenoviruses (OAdv) have been extensively stud-
ied and tested in clinical trials involving a variety of cancer
types. Results from those clinical trials revealed good toxico-
logical and safety profile, but modest efficacy [1]. OAdv face
numerous challenges that hinder their successful application.
Upon systemic administration, OAdv can be filtered and
retained in normal tissues, especially the liver. The immune
system can recognize the adenovirus in the bloodstream lead-
ing to its elimination. Moreover, to exit the bloodstream and
enter the extracellular space, virus particles have to overcome
the abnormal tumor vascular system [2] and the elevated
interstitial fluid pressure [3]. Finally, the tumor microenvi-
ronment contains several barriers that limit drug penetration
and delivery, such as an extracellular matrix (ECM) rich
in proteins, hyaluronic acid, proteoglycans, and stromal
cells [4, 5].
The use of cell carriers to deliver oncolytic viruses to pri-
mary tumors and metastases addresses many of these obsta-
cles. In this regard, some types of stem cells have garnered
significant interest due to their capability to migrate specifi-
cally toward tumors [6, 7]. Thus, systemic administration of
autologous and allogeneic stem cells loaded with the oncoly-
tic virus could evade the filtering organs and the immune
system and cross the endothelial barrier.
Mesenchymal stem cells (MSCs) are adult stem cells,
which can be isolated and expanded ex vivo from a great
variety of sources and species [8].MSCs are considered tohave
low immunogenicity owing to their unique immunologic
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characteristics: MSCs express low levels of HLA class I, but
neither HLA class II nor CD40, CD80, and CD86 costimula-
tory molecules on their surface [9]. Moreover, MSCs induce
little proliferation of allogeneic lymphocytes and modulate
the activity of cytotoxic T cells, dendritic cells, and B cells
[10, 11]. In addition, MSCs are known to migrate to sites of
injury and inflammation, which are two characteristics of
the tumor microenvironment [12, 13]. All these attributes
makeMSCs particularly appealing as cell carriers for oncolytic
viruses. In fact, proof of principle of MSCs as cell carriers for
OAdv has been demonstrated in several animal models
[14–16], and their efficacy has been evaluated in a clinical
trial for cancer treatment [17, 18].
The bone marrow represents the main and most frequent
source for MSC isolation and amplification. Nonetheless, the
invasive methods used to obtain these cells, the low number
of MSCs present in bone marrow (0.001–0.01% total nuclear
cells [19]), and their slow and restricted in vitro expansion
represent major obstacles for their use in cancer treatment.
It would be therefore preferable to identify an alternative
source of MSCs that allow an easy isolation without clinical
intervention or hospitalization and with a high content of
cells to minimize in vitro expansion.
In 2004, Chan and coworkers showed the existence of a
mesenchymal cell population in the human endometrium
which represents approximately 1% of endometrial cells
[20]. Later on, Patel et al. demonstrated that the shed men-
strual blood and tissue represents a rich source for these
endometrium mesenchymal stem cells, suggesting that it
was not necessarily an invasive procedure (hysterectomia or
biopsia) for their obtention [21]. It was further confirmed
that menstrual blood-derived mesenchymal stem cells were
positive for mesenchymal stem cell markers, can be rapidly
expanded without chromosomal aberration, and can differ-
entiate into a variety of cell types from the three germ layers
(feature characteristic of mesenchymal stem cells) [22]. In
2013, the group of Filippo Rossignoli compared MSCs iso-
lated from different origins (bone marrow, peripheral blood,
dental pulp, umbilical cord, adipose tissue, and decidual tis-
sue) and determined that MenSCs resemble more closely to
bone marrow-derived MSCs than MSCs obtained from other
tissues. Furthermore, they demonstrated that MenSCs have
the shortest population doubling time, the highest clonogenic
efficacy, and the largest number of in vitro passages before
becoming senescent [23]. More recently, MenSCs have been
extensively characterized in vitro and in vivo and their
potential for cellular therapy has been described [24–26].
Altogether, these features point out that menstrual blood
represents an efficient and ethically accepted source of MSCs
for clinical treatments.
Currently, the use of MenSCs has been applied to the
treatment of multiple sclerosis, Duchenne muscular dystro-
phy, and more recently, heart failure and liver cirrhosis
(reviewed in [26]). Here, we propose the use of MenSCs as
cell carriers for OAdv and cancer treatment.
In this study, we show the proliferative potential of
menstrual blood-derived mesenchymal stem cells and
demonstrate that MenSCs can be efficiently infected with
different Ad5-based capsid-modified adenoviruses, leading
to viral replication and release of new viral progeny. Finally,
using in vivo imaging studies in mice, we demonstrate that
MenSCs loaded with an oncolytic adenovirus (OAdv)
present tumor tropism upon regional administration.
Our results indicate that MenSCs represent a promising
candidate as cell carriers for oncolytic adenovirus delivery
to human tumors.
2. Materials and Methods
2.1. Cell Culture
2.1.1. Isolation of Human Menstrual Blood-Derived
Mesenchymal Stem Cells. Menstrual blood (1–5ml) was col-
lected from healthy female donors (n = 7), aged 23–42 years,
on the first 3 days of the menstrual phase using a menstrual
cup (Mooncup, Brighton, UK). The protocol and cell dona-
tion for research purposes were approved by the Institutional
Ethics Committee, and written consent was signed for each
donor. Blood samples were transferred to a sterile 50ml cen-
trifuge tube with conical bottom, filled with sterile phosphate
buffered saline (PBS, Life Technologies, Carlsbad, CA, USA),
and centrifuged at 1500 rpm for 5 minutes. The pellet was
resuspended in α-MEM (Life Technologies) containing 20%
fetal bovine serum, 1% penicillin/streptomycin, and 1% gen-
tamicin/amphotericin B (all from Life Technologies) and
seeded overnight in culture flasks (Corning Inc., Corning,
NY) at 37°C in a 5% CO2 atmosphere.
The next day, cell monolayer was washed once with
PBS to remove nonadherent cells and cellular debris and
replaced with fresh medium. Finally, MenSCs were ampli-
fied for 7–24 days (passage 0), substituting the culture
medium every 3-4 days, until 75%–90% confluent, and
then passaged periodically by detachment (0.25% trypsin-
1mM EDTA in PBS (Life Technologies)) after achieving
a subconfluent monolayer.
2.1.2. Bone Marrow-Derived Mesenchymal Stem Cells. BM-
MSCs were obtained from the American Type Culture
Collection (ATCC, Manassas, VA) and maintained with α-
MEM (Life Technologies) supplemented with 15% fetal
bovine serum and 1% penicillin/streptomycin (all from
Invitrogen) at 37°C, 5% CO2.
2.1.3. Cell Lines. A549 (human lung adenocarcinoma),
SKmel28 (human melanoma), and Panc-1 (human pancre-
atic adenocarcinoma) were obtained from the American
Type Culture Collection (ATCC, Manassas, VA). NP-18
pancreatic tumor cell lines were established in our laboratory
[27]. All tumor cell lines were maintained with Dulbecco’s
modified Eagle’s medium supplemented with 5 or 10% fetal
bovine serum and 1% penicillin/streptomycin (all from Invi-
trogen) at 37°C, 5% CO2. All cell lines were routinely tested
for mycoplasma presence.
2.2. Phenotypic Characterization. MenSCs (passage 3) were
analyzed by flow cytometry for expression of the different cell
surface markers. Fluorescein isothiocyanate- (FITC-) conju-
gated antibodies against CD29 (Immunostep, Salamanca,
Spain), CD90 (eBioscience, San Diego, CA, USA), HLA-DR,
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CD14, CD34, CD83, CD86 (BD Biosciences, San Jose,
CA, USA), CD40 (Biolegend, San Diego, CA, USA),
phycoerythrin- (PE-) conjugated antibody against CD73
(BD biosciences), CD105a (eBiosciences) CD133 (Miltenyi
Biotec, Bergisch Gladbach, Germany), and Alexa Fluor
700-conjugated antibody against CD44 (BD Biosciences)
were used. The corresponding fluorescent, isotype-matched
negative control antibodies defined background staining.
Harvested MenSCs were washed with PBS containing 1%
bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, MO)
and 0.1% sodium azide (Sigma-Aldrich). Aliquots of 2× 105
cells were next incubated on ice with the corresponding
antibody, at the concentration recommended by the
manufacturer, for 20min and under light protection. A
Gallios cytometer (Beckman Coulter, Brea, CA, USA) was
used, and 10,000 events were analyzed for each sample.
FlowJo v7.6.5 (Tree Star Inc., San Carlos, CA, USA) software
was used for the analysis of the data.
2.3. In Vitro Differentiation of MenSCs. MenSCs (passage 3)
were plated in 12-well plates with α-MEM containing 20%
fetal bovine serum, 1% penicillin/streptomycin, and 1%
gentamicin/amphotericin B and used for the differentiation
study when reached at 80%–90% of confluence.
Adipogenic, chondrogenic, and osteogenic differentia-
tion were induced by culturing the cells with commercial dif-
ferentiation media (all from Life Technologies). To confirm
correct differentiation after 14–21 days in culture, oil red O
staining for lipid droplets, alcian blue staining for sulfated
proteoglycan-rich matrix, and alizarin red staining to detect
calcified extracellular matrix deposits were performed to
confirm correct adipogenic, chondrogenic, and osteogenic
differentiation, respectively. Nondifferentiated but stained
MenSCs as stained controls were also included.
2.4. Colony-Forming Unit (CFU) Assay. MenSCs from 5 dif-
ferent donors (passages 4–6) and BM-MSCs (passage 5) were
seeded at clonal density of 500–1000–2000 cells/cm2 in
6-well cell culture plates. After 10 days in culture, cells were
washed with PBS, fixed with methanol for 10 minutes, and
stained with 0.5% crystal violet for 20 minutes at room
temperature and the corresponding colonies were counted.
2.5. Population Doubling Time. The population doubling
time (DT) was assessed by seeding 10,000 MenSCs (from 5
different donors, passages 4–6) or BM-MSCs (passage 5) in
6-well cell culture plates with complete medium and count-
ing the cell number at days 3, 5, 7, and 10 of culture. The
DT was determined using a doubling time calculation
software equation (Roth V. 2006 http://www.doubling-time.
com/compute.php).
2.6. Generation of Recombinant Adenoviruses and Adenoviral
Vectors. Adenoviral vectors AdGL (wild-type capsid),
AdGLRGD (insertion of Arg-Gly-Asp (RGD) in the
HI-loop of the fiber knob), and AdGLK (replacement
of the KKTK fiber shaft heparan sulfate glycosaminoglycan-
binding domain with an RGDK motif) expressing the
EGFP-luciferase fusion protein cassette [28, 29] and
the oncolytic adenovirus ICOVIR15 [30] have been
previously described.
2.7. Viral Infectivity Assays.MenSCs (passage 3) were seeded
in 24-well plates (5× 104 cells/well) and infected with the
adenoviral vectors AdGL, AdGL-RGD, and AdGLK at differ-
ent multiplicity of infection (MOI 25, 10, 5, and 1 TU/cell) in
triplicates during 24 hours at 37°C. After this time, cells were
trypsinized and resuspended in FACS buffer (PBS 10%
FBS, 0.01% sodium azide), and 5000 events were analyzed
by flow cytometry.
2.8. Flow Cytometry Analysis of Coxsackievirus-Adenovirus
Receptor (CAR) and Integrin Expression. MenSCs (1× 105
cells/sample) (passage 3) were harvested by trypsin digestion
and labeled with either mouse monoclonal anti-CAR RmcB
(Upstate Biotechnology, Lake Placid, NY, USA) or mouse
monoclonal anti-αv-integrin L230 (Enzo Life Sciences,
Farmingdale, NY, USA) for 1 h at 4°C. Subsequently, cells
were incubated with Alexa Fluor 488-labeled goat anti-
mouse IgG (Life Technologies) for 1 h at 4°C. A background
control incubated only with secondary antibody was also
included. Finally, samples were analyzed by flow cytometer.
2.9. Viral Production Assay.MenSCs, BM-MSCs (1× 105 cells
per well in 24-well plates, both at passage 4) and A549 cells
(2× 105 cells per well in 24-well plates) were infected at a
MOI of 50 TU/cell (MSCs) and 10 TU/cell (A549). Four
hours after infection, medium was removed and cells were
washed thrice with PBS and incubated with fresh medium.
At the indicated time points of postinfection (0, 24, 48, and
72 h), a small fraction of the supernatant (SN) was collected,
and the cells and the medium were harvested and frozen-
thawed three times to obtain the cell extract (CE). Viral titers
were determined in triplicate by an antihexon staining-based
method in HEK293 cells [31].
2.10. In Vitro Cytotoxicity Assays. MenSCs (passage 4) were
infected with ICOVIR15 at a MOI of 50 TU/cell for 24 h.
The next day, infected MenSCs were washed thrice with
PBS and cocultured with tumor cell lines (A549, Panc-1,
NP-18, and SKmel28) at different MenSC : tumor cell ratios
ranging from 1 : 1 to 0.001 : 1. At day 5 of coculture, plates
were washed with PBS and stained for total protein content
(bicinchoninic acid assay; Pierce Biotechnology, Rockford,
IL) and absorbance was quantified. The ratio MenSC : tumor
cell required to produce 50% tumor cell growth inhibition
(IC50) was determined from dose-response curves by
standard nonlinear regression (GraphPad Prism; GraphPad
Inc., La Jolla, CA).
2.11. MSC Staining with DiR. To allow in vivo tracking of
MSCs, BM-MSCs and MenSCs (both at passage 7) were
stained with XenoLight DiR, a near-IR lipophilic membrane
dye (PerkinElmer, Waltham, MA, USA). MSCs were incu-
bated with 320μg/ml of DiR for 30min at 37°C according
to the manufacturer’s protocol.
The DiR-labeled MSCs were spinned down for 5min at
1000 rpm, and cell pellets were resuspended in PBS. This
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procedure was repeated twice to ensure complete removal of
any unbound dye.
2.12. In Vivo Tumor-Homing Studies. In vivo studies were
performed at the ICO-IDIBELL facility (Barcelona, Spain)
AAALAC unit 1155 and approved by IDIBELL’s Ethical
Committee for Animal Experimentation.
Subcutaneous xenograft tumors were established by
injection of 5× 106 A549 cells into the flanks of 9-week-old
female athymic nu/nu mice. When tumors reached
400mm3, 1× 106 DiR-labeled MenSCs (passage 7) were
administered intraperitoneally or intratumorally in mice
(n = 3). Fluorescence images (using 10nm excitation and
780nm emission filters) were monitored at 1 h, 24 h, 48 h,
and 5 days postadministration which allowed MSC-homing
determination using IVIS Lumina bioimaging system
(PerkinElmer). Images were analyzed with IVIS Living
Image (PerkinElmer) software. Regions were manually
drawn around the tumors.
The same model was used to evaluate the effect of OAdv
infection in MSC tumor tropism. When tumors reached
400mm3, mice (experimental day 0) were randomized
(n = 5 animals per group) into the following groups: PBS,
BM-MSCs (previously labeled with DiR); MenSCs (previ-
ously labeled with DiR); BM-MSCs-OAdv (BM-MSCs
previously infected with ICOVIR15 at MOI 50 for 2 h and
labeled with DiR); and MenSCs-OAdv (MenSCs previously
infected with ICOVIR15 at MOI 50 for 2 h and labeled with
DiR). Animals received a single intraperitoneal administra-
tion of PBS, 1 × 106 BM-MSCs; BM-MSCs-OAdv; MenSCs
or MenSCs-OAdv. Fluorescence images monitored at 24h,
48 h, and 72h postadministration. Images were analyzed
with IVIS Living Image (PerkinElmer) software. Regions
were manually drawn around the tumors.
2.13. Statistical Analysis. Statistical comparisons between
groups were performed using the Mann–Whitney U test
(2-tailed) when n > 3. Statistical significance was established
as P < 0 05. Data are presented as the mean± SD. All statistical
analyses were calculated with the GraphPad Prism software.
3. Results
3.1. Isolation and Characterization of Human MenSCs.Men-
strual blood (1–5ml) was collected from healthy female
donors (n = 7) aged 23–42 years on the first 3 days of the
menstrual phase, and mesenchymal stem cells were isolated.
After one week in culture, adherent cells exhibited a spindle-
shaped fibroblast-like morphology reaching confluence after
7–24 days of culture (Supplementary Fig. 1A available online
at https://doi.org/10.1155/2017/3615729).
Using commercially available media, MenSCs were
induced to differentiate into 3 mesodermal lineages (adipo-
genic, chondrogenic, and osteogenic) in order to examine
their multipotentiality. After 21 days in culture with the
different media, lipid vesicles were observed by phase-
contrast light microscopy and contrasted with oil red O stain
(Supplementary Fig. 1B, left). Alcian blue staining confirmed
the presence of sulfated proteoglycan-rich matrix on the
chondrogenic MenSC differentiation (Supplementary Fig.
1C, left). Finally, differentiation of MenSCs into osteoblasts
was confirmed after cell morphology changed from a
spindle-shaped to a cuboidal-like phenotype, forming cell
aggregates, and calcium deposition was observed by staining
these cells with alizarin red (Supplementary Fig. 1D, left).
MenSCs were also characterized by the expression of
several mesenchymal stem cell antigens (CD29, CD90,
CD44, CD73, and CD105a) and the absence of hemato-
poietic markers (CD34, HLA-DR, CD133, and CD14)
and costimulatory proteins (CD40, CD83, and CD86)
(Supplementary Fig. 2).
Altogether, these results are in agreement with the cri-
teria to define human MSCs established by the International
Society for Cellular Therapy (ISCT) [32].
3.2. Growth Characteristics of MenSCs. To compare differ-
ences in growth potential between MenSCs and BM-MSCs,
we first determined the population doubling time (DT) of
MenSCs from five donors and commercial BM-MSCs. All
MenSCs presented a significantly reduced population
DT (39.7± 2.3 h), compared with BM-MSCs (63.6 h)
(Figure 1(a)), without correlation between the donor age
and the DT (linear regression donor age versus DT r2 = 0 6).
Furthermore, a colony-forming unit (CFU) assay was
performed by seeding the MenSC lines and BM-MSCs at dif-
ferent cell densities. The clonogenic ability of all MenSC cell
lines was significantly higher than that of BM-MSCs inde-
pendently of the initial cell density (ratio MenSC/BM-MSC
colonies of 3.2± 0.9, 3.7± 1.0, and 4.6± 1.1 when seeding at
500, 1000, and 2000 cells/cm2, resp.) (Figure 1(b)).
These data demonstrate that MenSCs have a greater
growth potential than BM-MSCs, not only because of their
higher clonogenic capability but also because of their shorter
population DT and faster cell growth kinetics.
3.3. Adenovirus Infection and Replication in MenSCs. To
determine the permissiveness of MenSCs to adenoviral infec-
tion and replication, several experiments were performed.
We first evaluated the efficacy of three different capsid-
modified adenovirus vectors to infect the mesenchymal cells.
MenSCs were infected with different amounts of AdGL
(wild-type capsid), AdGLRGD (insertion of Arg-Gly-Asp
(RGD) in the HI-loop of the fiber knob), and AdGLK
(replacement of the KKTK fiber shaft heparan sulfate
glycosaminoglycan-binding domain with an RGDK motif).
As shown in Figure 2(a), while wild-type capsid and the cap-
sid containing the RGD in the fiber shaft poorly infected
MenSCs even at high MOI, the capsid with the RGD in the
HI-loop of the fiber allowed an efficient infection even at
the low MOI of 5 TU/cell. A possible explanation for these
results is the absence of the coxsackievirus B and adenovirus
receptor (CAR) (required for the initial attachment of Ad5 to
cell surface) and the presence of αv-integrins (required for
the second interaction through the RGD motif located on
the penton base protein of the capsid) on the surface of
MenSCs (Figure 2(b)). Therefore, whereas MenSCs lack the
primary receptor of wild-type and RGDK capsids (AdGL
and AdGLK), the insertion of the RGD in the fiber knob
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(AdGLRGD) allows the efficient use of integrins as a primary
receptor instead of CAR, increasing MenSC infectivity.
We next evaluated the ability of MenSCs to allow adeno-
virus replication. Figure 2(c) shows the production of new
viral particles from MenSCs, BM-MSCs, and A549 (a highly
permissive epithelial tumor cell line commonly used for pro-
duction of oncolytic adenoviruses) infected with ICOVIR15.
The MOI used for MSC was 50 TU/cell (to ensure 100%
infection) whereas for A549, the MOI was 10 TU/cell.
Although the kinetics of viral production in MenSCs
and BM-MSCs is delayed in the first 24 h compared to
A549, the total production yield after 72 h is only 1.5-fold
lower in MenSCs and 1.6-fold lower in BM-MSCs than
in A549 (2237 TU per A549 cell versus 1455 TU per
MenSCs and 1362TU for BM-MSCs). These results
clearly demonstrate that MenSCs are permissive for onco-
lytic adenovirus replication.
Once the capability of infected MenSCs to generate new
adenovirus particles is demonstrated, we next tested whether
an oncolytic adenovirus produced within MenSCs could kill
different cancer cell lines in an in vitro coculture system.
MenSCs were infected with ICOVIR15 at a MOI of 50 TU/
cell for 24h. The next day, infected MenSCs were cocultured
with cancer cell lines at different infected MenSCs : cancer
cell ratios. As shown in Figure 2(d), coculture of infected
MenSC with cancer cell lines resulted in an efficient death
of cancer cell lines after 5 days of coculture, with an IC50
(number of infected MenSCs necessary to eliminate 50% of
cancer cells) ranging from 0.0047 to 0.086.
3.4. MenSCs Infected with an Oncolytic Adenovirus Migrate
to Subcutaneous Xenograft Tumor In Vivo. To test the
homing capacity of MenSCs to subcutaneous tumors
in vivo after regional administration (intraperitoneal),
1× 106 DiR-labeled MenSCs were administered intraperito-
neally or intratumorally in A549 tumor-bearing immuno-
deficient mice. One hour after administration, fluorescent
signal was detected in the tumors of all treated animals,
showing approximately a 10-fold higher signal after 24 h
without significant variations until day 5 when animals
were sacrificed (Figure 3(a)). As expected, fluorescence
signal in tumors administered intratumorally was higher
than that administered intraperitoneally. However, the
presence and enrichment of MenSCs in the tumor after
intraperitoneal administration (the fluorescence signal at
day 5 was 4.2 times higher than at 1 h postadministration)
demonstrate the tumor tropism of MenSCs in this model
(Figure 3(b)).
One concern regarding the use of MSCs as cell carriers
for adenovirus delivery to tumors is a possible loss of tumor
tropism due to virus infection. We compared the homing
capability to subcutaneous xenograft tumors of infected and
uninfected MenSCs and BM-MSCs. A549 tumor-bearing
mice were injected intraperitoneally with 1× 106 of DiR-
labeled BM-MSCs, MenSCs, BM-MSCs-OAdv (BM-MSCs
previously infected with ICOVIR15 at MOI 50 for 2 h),
and MenSCs-OAdv (MenSCs previously infected with
ICOVIR15 at MOI 50 for 2 h), and cells were imaged at
24 h, 48 h, and 72 h postadministration. As shown in
Figure 3(c), labeled cells from all groups could be detected
in tumors at 24 h postadministration, with a higher signal
at 48 h and 72 h (not significant) suggesting a progressive
accumulation of the administered cells in tumors over
time. Quantification of fluorescence signal at the different
time points (Figure 3(d)) demonstrates the same capability
of tumor homing for BM-MSCs and MenSCs, independent
of oncolytic adenovirus infection. The slight difference
(not statistically significant) between uninfected versus








































Figure 1: Growth potential of MenSCs. (a) 10,000MenSCs (from 5 different donors) or BM-MSCs were seeded in 6-well plates with complete
medium, and the cell number was counted at days 3, 5, 7, and 10 of culture. (b) Colony-forming unit (CFU) efficiencies of MenSCs (from 5
different donors) and BM-MSCs, plated at a 500, 1000, and 2000 cells/cm2 in 6-well plates. After 10 days of culture, cells were stained with
crystal violet and the corresponding colonies were counted.
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infected BM-MSCs and uninfected versus infected MenSCs
(solid line versus dotted line for each cell type) was prob-
ably due to the progressive replication of the virus in the
infected MSCs that led to cell lysis.
4. Discussion
In the present work, we have studied the phenotype and
growth properties of MenSCs isolated and cultured from










































































































IC50 0.0047 IC50 0.041
IC50 0.0065 IC50 0.086
Infected MenSC : cancer cell Infected MenSC : cancer cell
Infected MenSC : cancer cell Infected MenSC : cancer cell
(d)
Figure 2: MenSC infection and viral replication. (a) Infectivity assay in MenSCs. MenSCs (5× 104 cells/well) were infected for 24 hours at
37°C with AdGL, AdGLRGD, and AdGLK at different multiplicities of infection (25, 10, 5, and 1 TU/cell). Infected cells were analyzed by
flow cytometry. Results are shown as the % of infected cells (green cells). Mean values (n = 3)± SD are represented. (b) MenSCs were
analyzed by flow cytometry for the expression of the main adenovirus type 5 receptors. MenSCs express αv-integrins but do not express
the coxsackievirus B and adenovirus receptor (CAR). (c) OAdv production kinetics and release in A549 cells, BM-MSCs, and MenSCs.
Extracellular (SN) and total virus produced (CE) were measured at the indicated time points. Mean values (n = 3)± SD are plotted.
(d) Cytotoxicity analysis of OAdv produced by MenSCs. A549, Panc-01, NP-18, and SKmel28 cancer cell lines were cocultured with
previously infected MenSCs (MOI of 50 TU/cell of ICOVIR15 for 24 h before coculture) at different infected MenSCs : cancer cell ratios.
At day 5 of coculture, cell survival was measured and IC50 values calculated. Mean values (n = 3)± SD are plotted.
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diverse donors. We have confirmed that isolated MenSCs are
morphologically very similar to bone marrow MSC, showing
the classical spindle-shaped fibroblast-like morphology of
MSCs, as previously described [21]. Moreover, the immuno-
phenotypic analysis revealed their mesenchymal stem cell
nature, and their capacity to differentiate into various meso-
dermal cell types (adipocytes, chondrocytes, and osteocytes)
confirmed their multipotency attribute which is also a
characteristic of MSCs [33].
The proliferative potential of MenSCs versus BM-MSCs
has been also evaluated. Through direct comparison experi-
ments, we have determined that MenSCs had a greater
growth potential than BM-MSCs, not only because of their
higher clonogenic capability but also because of their shorter
population DT and their near to exponential cell growth
kinetics. Furthermore, we did not observe any inverse corre-
lation between the donor age and the number of MSC
























































































Figure 3: Tumor tropism of MenSCs. (a) A549 tumor-bearing immunodeficient mice (n = 3) were administered with 1× 106 DiR-labeled
MenSCs intratumorally (IT) or intraperitoneally (IP), and fluorescence signal was detected using an in vivo imaging system (IVIS) at the
indicated time points after cell administration. At the end of the experiment (5d), tumors were harvested and exposed to fluorescence
analysis. (b) Intensity of fluorescence in tumors was quantified with the IVIS living image software. Mean values (n = 3)± SD are
represented. (c) To evaluate the impact of OAdv infection on tumor-homing capacity of MenSCs and BM-MSCs, A549 tumor-bearing
immunodeficient mice (n = 5) were injected intraperitoneally with 1× 106 of BM-MSCs (previously labeled with DiR), MenSCs (previously
labeled with DiR), BM-MSCs-OAdv (BM-MSCs previously infected with ICOVIR15 at MOI 50 for 2 h and labeled with DiR), and
MenSCs-OAdv (MenSCs previously infected with ICOVIR15 at MOI 50 for 2 h and labeled with DiR). Fluorescence signal was detected
using IVIS at the indicated time points after cell administration. (d) Intensity of tumor fluorescence was quantified with IVIS software.
Mean values (n = 5)± SD are plotted. No statistical differences in tumor fluorescence values were observed between mesenchymal from
different origins (bone marrow versus menstrual blood) and between infected and noninfected cells for each cell type (BM-MSC versus
BM-MSC+OAdv and MenSC versus MenSC+OAdv) at any time points analyzed (Mann–Whitney U test).
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potential, contrary to what has been described for bone
marrow-derived mesenchymal stem cells [34]. These features
also represent an advantage in using MenSCs rather than
MSCs from other sources, especially when high amount of
cells are needed in a short period of time.
Infectivity, viral replication and release of new viral parti-
cles are required properties for MenSCs in order to their
application as cell carriers for oncolytic adenoviruses. These
features were evaluated in the present work step by step. First,
we analyzed the infectivity of MenSCs by three different
capsid-modified adenovirus vectors. Our results indicate that
while wild-type capsid poorly infects MenSCs, virus carrying
an extra RGD motif in the HI-loop of the fiber knob can effi-
ciently infect MenSCs, even at low MOIs. As previously
described for BM-MSCs [35], the analysis of adenovirus sero-
type 5 receptors in the surface of MenSCs showed the
absence of the coxsackievirus B and adenovirus receptor
(CAR), and the presence of αv-integrins, indicating that the
insertion of the RGD in the fiber knob probably allows the
use of integrins as a primary receptor instead of CAR, which
could explain the increase of infectivity by this modified cap-
sid. We next evaluated the OAdv production in MenSCs
compared with BM-MSCs and A549 cells, demonstrating a
similar viral production and release from MenSCs and BM-
MSCs, being only 1.5 times lower than A549. Last, the onco-
lytic capacity of the viral progeny released from infected
MenSCs was demonstrated in vitro, as culturing 1 infected
MenSC for each 11(SKmel28)-213(A549) tumor cell (numer-
ical transformation from IC50 established from this experi-
ment (1 infected MenSC/IC50) = number of tumor cells)
could eliminate 50% of cancer cells in 5 days. Altogether,
these results represent, to our knowledge, the first report
demonstrating the capability of MenSCs to generate and
release functional oncolytic adenovirus particles.
Tumor homing for OAdv-infected MSCs has been
reported not only after local administration as intracranial
[36, 37] or intraperitoneal [38, 39], but also after intravenous
administration in orthotopic mouse models [40] and subcu-
taneous xenograft mouse models [41, 42]. To study if
MenSCs retain this tumor tropism observed in other MSCs,
we evaluated MenSC migration in a subcutaneous xenograft
tumor model after intraperitoneal administration. The intra-
venous administration was not considered for our experi-
mental design since MSCs are retained in the lung due to
their size [43], and considering that adenovirus replication
cycle is completed after 72–96h, the virus would kill the cells
before reaching the tumors. Our in vivo results show that, in
our tumor model, both MenSCs and BM-MSCs display the
same tumor-homing properties, which are not affected by
OAdv infection.
Altogether, we show that MenSCs represent a realistic
alternative to BM-MSCs as OAdv cell carriers. Through
direct comparison, we demonstrate that they share the same
properties regarding viral amplification and tumor homing.
In addition, the switch from bone marrow to menstrual
blood as source for MSCs involves important advantages
including (i) wide availability since millions of potential
donors could be used periodically; (ii) low cost, as no
clinical intervention or hospitalization is needed; and
(iii) faster, due to their increased growth kinetics. MenSCs
face, however, limitations in applications requiring autolo-
gous MSCs, since only women before menopause could be
considered as donors.
Finally, in addition to the potential of MenSCs as surro-
gate of BM-MSCs, they can also be considered as an alterna-
tive to the use of naked OAdv. The use of cell carriers for
OAdv could represent an advantage in those cases where
the use of naked OAdv would be especially challenging, such
as in patients with high levels of anti-Ad5 neutralizing anti-
bodies (NAbs) or when readministration is required (usually
not effective due to the immunity generated by the first
administration). Theoretically, hiding the virus to the
immune system using cell carriers could avoid the neutraliza-
tion of the virus by NAbs, leading to a higher antitumor
efficacy. Despite this protection from NAbs still needs to be
demonstrated, an increase in the viral persistence has been
reported after administration of OAdv-loaded bone
marrow-derived mesenchymal stem cells in an immunocom-
petent model, associated with the capacity of MSCs to
immunosuppress the antiviral immune response [44].
5. Conclusions
Menstrual blood-derived mesenchymal stem cells can be
easily isolated, amplified, and infected with different Ad5-
based capsid-modified adenoviruses. Adenovirus-infected
menstrual blood-derived mesenchymal stem cells produce
and release viral progeny and home tumors upon regional
administration.
The use of menstrual blood-derived mesenchymal stem
cells as carriers for oncolytic adenoviruses to human tumors
warrants further testing towards clinical application.
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